FDA Approved New PAH Drug from Actelion

Marta Ribeiro avatar

by Marta Ribeiro |

Share this article:

Share article via email

ph_fda

According to a recent announcement, the United States Food and Drug Administration (FDA) approved Actelion Pharmaceuticals’ Uptravi (selexipag) tablets for the treatment of adult patients with pulmonary arterial hypertension (PAH) to delay disease progression and reduce the risk of hospitalization, under orphan drug designation.

PAH is a life-threatening disease characterized by high blood pressure and abnormal constriction of the pulmonary artery. The condition causes the heart to work faster and elevates blood pressure in arteries within the lungs, potentially causing fatal heart failure and other, less serious, complications and disturbances in quality of life.

 

Read more about it: http://bit.ly/1Jrfx5F

Print This Page

About the Author

Marta Ribeiro avatar
Marta Ribeiro Marta graduated from Universidade Fernando Pessoa in Porto with a degree in Communication Sciences and a Masters degree in New Communication Technologies. She has experience in social media, worked with several media channels, and has also worked as a freelance photographer and a graphic artist for almost 10 years.

Tags

FDA, FDA approval, PAH, pulmonary arterial hypertension (PAH), pulmonary hypertension, Pulmonary hypertension (PHT), Selexipag, Uptravi (selexipag)

Recent Posts


A Conversation With Rare Disease Advocates

Recommended reading